ADC For Multi-Drug Resistant Gram-negative Bacterial Infections

Cloudbreak Antibody Drug Conjugates (ADC) offer several added benefits over small molecule approaches for use as highly effective countermeasures against MDR bacterial infections.

Different from traditional antibiotics, the Cloudbreak ADCs physically link the pathogen and the immune component to eradicate pathogens via dual killing mechanisms. The engagement of specific innate immune system components confers potential to largely limit resistance development in target pathogens. Furthermore, by linking to an antibody Fc, ADCs possess extended half-lives to support once-weekly or bi-weekly dosing, making them well suited as both immunoprophylactic and immunotherapeutic agents to prevent and treat life-threatening multidrug-resistant Gram-negative infections.

Advantages of Gram-negative Antimicrobial Antibody Drug Conjugate (ADC)
Direct kill: novel TMs tightly bind LPS and kill bacteria – KAPE spectrum
Immunomodulatory: Fc recruits and initiates an innate immune system response
Superior PK/ADME: Antibody-like PK, receptor mediated transport to lung, limited kidney exposures
Potentiation: Enhances permeability of standard of care therapeutics to provide additional efficacy
Protection from septic shock: Attenuation of sepsis response through LPS scavenging

Multi-Drug Resistant Gram-negative Bacteria

Many strains of bacteria have mutated over time and have developed resistance to existing antibiotics resulting in limited therapeutic options for patients and a growing public health crisis. Antibiotic resistance is seen in both community- and hospital-acquired infections and is of most concern for patients with bacterial infections that are resistant to a number of antibiotic classes. These bacteria are referred to as multi-drug resistant (MDR). MDR Gram-negative bacteria include strains of Acinetobacter, Pseudomonas and Klebsiella, which can lead to serious, life-threatening infections in the absence of effective new treatments.